Kalvista Pharmaceuticals宣布欧盟委员会和瑞士医药管理局批准Ekterly®(Sebetralstat),这是首个也是唯一的遗传性血管水肿口服按需治疗药物

美股速递
Sep 19

Kalvista Pharmaceuticals宣布,欧盟委员会和瑞士医药管理局已批准其药物Ekterly®(Sebetralstat)上市。该药物是治疗遗传性血管水肿的首个也是唯一的口服按需治疗药物。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10